Correction: Identification of peptidoglycan hydrolase constructs with synergistic staphylolytic activity in cow's milk [Appl Environ Microbiol, 83, 7 (2017), e03445-16]doi 10.1128/AEM.03445-16;Identification of peptidoglycan hydrolase constructs with synergistic staphylolytic activity in cow's milk

Applied and Environmental Microbiology

Volumn 83, Issue 7, 2017, Pages

  Verbree, Carolin T ^a   Dätwyler, Steven M ^a   Meile, Susanne ^a   Eichenseher, Fritz ^a   Donovan, David M ^b   Loessner, Martin J ^a   Schmelcher, Mathias ^a  

^a ETH ZURICH   (Switzerland)

^b AGRICULTURAL RESEARCH SERVICE   (United States)

Author keywords

Antibiotic resistance; Antimicrobial agents; Bovine mastitis; Peptidoglycan hydrolases; Bacteriophages; Endolysin; Mastitis; Protein engineering

Indexed keywords

ANTIBIOTICS; ANTIMICROBIAL AGENTS; BACTERIA; BACTERIOPHAGES; DISEASES; ENZYME INHIBITION; GEOGRAPHICAL REGIONS; HYDROLASES; MAMMALS;

ANTIBIOTIC RESISTANCE; BOVINE MASTITIS; ENDOLYSIN; MASTITIS; PEPTIDOGLYCANS; PROTEIN ENGINEERING;

DAIRY PRODUCTS;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIUM; BIOTECHNOLOGY; CATTLE; ENZYME; ENZYME ACTIVITY; MILK; PROTEIN;

BACTERIA (MICROORGANISMS); BOVINAE; STAPHYLOCOCCUS AUREUS;

ANTIINFECTIVE AGENT; N ACETYLMURAMOYLALANINE AMIDASE; PEPTIDOGLYCAN; RECOMBINANT PROTEIN;

ANIMAL; BOVINE; CATTLE DISEASES; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; GENE LIBRARY; GENETICS; HEAT; MASTITIS, BOVINE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MILK; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; UDDER; VETERINARY;

ANIMALS; ANTI-BACTERIAL AGENTS; CATTLE; CATTLE DISEASES; DRUG DISCOVERY; DRUG SYNERGISM; FEMALE; GENE LIBRARY; HOT TEMPERATURE; MAMMARY GLANDS, ANIMAL; MASTITIS, BOVINE; MICROBIAL SENSITIVITY TESTS; MILK; N-ACETYLMURAMOYL-L-ALANINE AMIDASE; PEPTIDOGLYCAN; RECOMBINANT PROTEINS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 85015961490     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.02134-17     Document Type: Erratum

References (46)

1. Götz F, Bannerman T, Schleifer KH. 2006. The genera Staphylococcus and Macrococcus, p 5-75. In Falkow S, Rosenberg E, Schleifer KH, Stackebrandt E (ed), The prokaryotes, vol 4. Springer, New York, NY.
2. Sordillo LM, Streicher KL. 2002. Mammary gland immunity and mastitis susceptibility. J Mammary Gland Biol Neoplasia 7:135-146. https://doi.org/10.1023/A:1020347818725.
3. Kerr DE, Plaut K, Bramley AJ, Williamson CM, Lax AJ, Moore K, Wells KD, Wall RJ. 2001. Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice. Nat Biotechnol 19:66-70. https://doi.org/10.1038/83540.
4. Taponen S, Pyörälä S. 2009. Coagulase-negative staphylococci as cause of bovine mastitis-not so different from Staphylococcus aureus? Vet Microbiol 134:29-36. https://doi.org/10.1016/j.vetmic.2008.09.011.
5. Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, Peters G. 2006. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 4:295-305. https://doi.org/10.1038/nrmicro1384.
6. Hebert A, Sayasith K, Senechal S, Dubreuil P, Lagace J. 2000. Demonstration of intracellular Staphylococcus aureus in bovine mastitis alveolar cells and macrophages isolated from naturally infected cow milk. FEMS Microbiol Lett 193:57-62.
7. Deluyker HA, Van Oye SN, Boucher JF. 2005. Factors affecting cure and somatic cell count after pirlimycin treatment of subclinical mastitis in lactating cows. J Dairy Sci 88:604-614. https://doi.org/10.3168/jds.S0022-0302(05)72724-7.
8. Vanderhaeghen W, Hermans K, Haesebrouck F, Butaye P. 2010. Methicillin-resistant Staphylococcus aureus (MRSA) in food production animals. Epidemiol Infect 138:606-625. https://doi.org/10.1017/S0950268809991567.
9. Schmelcher M, Donovan DM, Loessner MJ. 2012. Bacteriophage endolysins as novel antimicrobials. Future Microbiol 7:1147-1171. https://doi.org/10.2217/fmb.12.97.
10. Pastagia M, Schuch R, Fischetti VA, Huang DB. 2013. Lysins: the arrival of pathogen-directed anti-infectives. J Med Microbiol 62:1506-1516. https://doi.org/10.1099/jmm.0.061028-0.
11. Roach DR, Donovan DM. 2015. Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage 5:e1062590. https://doi.org/10.1080/21597081.2015.1062590.
12. Gutierrez D, Ruas-Madiedo P, Martinez B, Rodriguez A, Garcia P. 2014. Effective removal of staphylococcal biofilms by the endolysin LysH5. PLoS One 9:e107307. https://doi.org/10.1371/journal.pone.0107307.
13. Fischetti VA. 2010. Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int J Med Microbiol 300:357-362. https://doi.org/10.1016/j.ijmm.2010.04.002.
14. Whisstock JC, Lesk AM. 1999. SH3 domains in prokaryotes. Trends Biochem Sci 24:132-133. https://doi.org/10.1016/S0968-0004(99)01366-3.
15. Schmelcher M, Shen Y, Nelson DC, Eugster MR, Eichenseher F, Hanke DC, Loessner MJ, Dong S, Pritchard DG, Lee JC, Becker SC, Foster-Frey J, Donovan DM. 2015. Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection. J Antimicrob Chemother 70:1453-1465. https://doi.org/10.1093/jac/dku552.
16. Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA. 2010. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 54:1603-1612. https://doi.org/10.1128/AAC.01625-09.
17. Becker SC, Roach DR, Chauhan VS, Shen Y, Foster-Frey J, Powell AM, Bauchan G, Lease RA, Mohammadi H, Harty WJ, Simmons C, Schmelcher M, Camp M, Dong S, Baker JR, Sheen TR, Doran KS, Pritchard DG, Almeida RA, Nelson DC, Marriott I, Lee JC, Donovan DM. 2016. Triple-acting lytic enzyme treatment of drug-resistant and intracellular Staphylococcus aureus. Sci Rep 6:25063. https://doi.org/10.1038/srep25063.
18. Schindler CA, Schuhardt VT. 1964. Lysostaphin: a new bacteriolytic agent for the Staphylococcus. Proc Natl Acad Sci U S A 51:414-421. https://doi.org/10.1073/pnas.51.3.414.
19. DeHart HP, Heath HE, Heath LS, LeBlanc PA, Sloan GL. 1995. The lysostaphin endopeptidase resistance gene (epr) specifies modification of peptidoglycan cross bridges in Staphylococcus simulans and Staphylococcus aureus. Appl Environ Microbiol 61:1475-1479.
20. Kusuma C, Jadanova A, Chanturiya T, Kokai-Kun JF. 2007. Lysostaphinresistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo. Antimicrob Agents Chemother 51:475-482. https://doi.org/10.1128/AAC.00786-06.
21. Wall RJ, Powell A, Paape MJ, Kerr DE, Bannerman DD, Pursel VG, Wells KD, Talbot N, Hawk HW. 2005. Genetically enhanced cows resist intramammary Staphylococcus aureus infection. Nat Biotechnol 23:445-451. https://doi.org/10.1038/nbt1078.
22. Schmelcher M, Powell AM, Becker SC, Camp MJ, Donovan DM. 2012. Chimeric phage lysins act synergistically with lysostaphin to kill mastitiscausing Staphylococcus aureus in murine mammary glands. Appl Environ Microbiol 78:2297-2305. https://doi.org/10.1128/AEM.07050-11.
23. Becker SC, Dong S, Baker JR, Foster-Frey J, Pritchard DG, Donovan DM. 2009 LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. FEMS Microbiol Lett 294:52-60. https://doi.org/10.1111/j.1574-6968.2009.01541.x.
24. O'Flaherty S, Coffey A, Meaney W, Fitzgerald GF, Ross RP. 2005. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. J Bacteriol 187:7161-7164. https://doi.org/10.1128/JB.187.20.7161-7164.2005.
25. Abaev I, Foster-Frey J, Korobova O, Shishkova N, Kiseleva N, Kopylov P, Pryamchuk S, Schmelcher M, Becker SC, Donovan DM. 2013. Staphylococcal phage 2638A endolysin is lytic for Staphylococcus aureus and harbors an inter-lytic-domain secondary translational start site. Appl Microbiol Biotechnol 97:3449-3456. https://doi.org/10.1007/s00253-012-4252-4.
26. Obeso JM, Martinez B, Rodriguez A, Garcia P. 2008. Lytic activity of the recombinant staphylococcal bacteriophage PhiH5 endolysin active against Staphylococcus aureus in milk. Int J Food Microbiol 128:212-218. https://doi.org/10.1016/j.ijfoodmicro.2008.08.010.
27. Becker SC, Swift S, Korobova O, Schischkova N, Kopylov P, Donovan DM, Abaev I. 2015. Lytic activity of the staphylolytic Twort phage endolysin CHAP domain is enhanced by the SH3b cell wall binding domain. FEMS Microbiol Lett 362:1-8. https://doi.org/10.1093/femsle/fnu019.
28. Mamo W, Rozgonyi F, Hjerten S, Wadström T. 1987. Effect of milk on surface properties of Staphylococcus aureus from bovine mastitis. FEMS\ Microbiol Lett 48:195-200. https://doi.org/10.1111/j.1574-6968.1987.tb02541.x.
29. Rodriguez-Rubio L, Martinez B, Donovan DM, Garcia P, Rodriguez A. 2013 Potential of the virion-associated peptidoglycan hydrolase HydH5 and its derivative fusion proteins in milk biopreservation. PLoS One 8:e54828. https://doi.org/10.1371/journal.pone.0054828.
30. Mao J, Schmelcher M, Harty WJ, Foster-Frey J, Donovan DM. 2013. Chimeric Ply187 endolysin kills Staphylococcus aureus more effectively than the parental enzyme. FEMS Microbiol Lett 342:30-36. https://doi.org/10.1111/1574-6968.12104.
31. Rodriguez-Rubio L, Gutierrez D, Donovan DM, Martinez B, Rodriguez A, Garcia P. 2016. Phage lytic proteins: biotechnological applications beyond clinical antimicrobials. Crit Rev Biotechnol 36:542-552. https://doi.org/10.3109/07388551.2014.993587.
32. Loessner MJ, Kramer K, Ebel F, Scherer S. 2002. C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates. Mol Microbiol 44:335-349. https://doi.org/10.1046/j.1365-2958.2002.02889.x.
33. Idelevich EA, von Eiff C, Friedrich AW, Iannelli D, Xia G, Peters G, Peschel A, Wanninger I, Becker K. 2011. In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin. Antimicrob Agents Chemother 55:4416-4419. https://doi.org/10.1128/AAC.00217-11.
34. Idelevich EA, Schaumburg F, Knaack D, Scherzinger AS, Mutter W, Peters G, Peschel A, Becker K. 2016. The recombinant bacteriophage endolysin HY-133 exhibits in vitro activity against different African clonal lineages of the Staphylococcus aureus complex, Including Staphylococcus schweitzeri. Antimicrob Agents Chemother 60:2551-2553. https://doi.org/10.1128/AAC.02859-15.
35. Djurkovic S, Loeffler JM, Fischetti VA. 2005. Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob Agents Chemother 49:1225-1228. https://doi.org/10.1128/AAC.49.3.1225-1228.2005.
36. Becker SC, Foster-Frey J, Donovan DM. 2008. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA. FEMS Microbiol Lett 287:185-191. https://doi.org/10.1111/j.1574-6968.2008.01308.x.
37. Lewis RE, Diekema DJ, Messer SA, Pfaller MA, Klepser ME. 2002. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother 49:345-351. https://doi.org/10.1093/jac/49.2.345.
38. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52:1. https://doi.org/10.1093/jac/dkg301.
39. Schmelcher M, Powell AM, Camp MJ, Pohl CS, Donovan DM. 2015. Synergistic streptococcal phage lambdaSA2 and B30 endolysins kill streptococci in cow milk and in a mouse model of mastitis. Appl Microbiol Biotechnol 99:8475-8486. https://doi.org/10.1007/s00253-015-6579-0.
40. Schleifer KH, Kandler O. 1972. Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol Rev 36:407-477.
41. Kuang Y, Jia H, Miyanaga K, Tanji Y. 2009. Effect of milk on antibacterial activity of tetracycline against Escherichia coli and Staphylococcus aureus isolated from bovine mastitis. Appl Microbiol Biotechnol 84:135-142. https://doi.org/10.1007/s00253-009-2008-6.
42. O'Flaherty S, Coffey A, Meaney WJ, Fitzgerald GF, Ross RP. 2005. Inhibition of bacteriophage K proliferation on Staphylococcus aureus in raw bovine milk. Lett Appl Microbiol 41:274-279. https://doi.org/10.1111/j.1472-765X.2005.01762.x.
43. Schmelcher M, Loessner MJ. 2014. Use of bacteriophage cell wallbinding proteins for rapid diagnostics of Listeria. Methods Mol Biol 1157:141-156. https://doi.org/10.1007/978-1-4939-0703-8_12.
44. Newbould FH. 1974. Antibiotic treatment of experimental Staphylococcus aureus infections of the bovine mammary gland. Can J Comp Med 38:411-416.
45. Jones RN, Barry AL, Gavan TL, Washington JA, II. 1985. Susceptibility tests: microdilution and macrodilution broth procedures, p 972-977. In Lennette EH, Balows A, Hausler WJ, Jr, Shadomy HJ (ed), Manual of clinical microbiology. American Society for Microbiology, Washington, DC.
46. Hall MJ, Middleton RF, Westmacott D. 1983. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother 11:427-433. https://doi.org/10.1093/jac/11.5.427.